Table 2 Patients characteristics
Parameters | Categories | N | % |
|---|---|---|---|
Breed | European shorthair or longhair | 154 | 85.6% |
Other breeds | 26 | 14.4% | |
Gender | Intact female | 112 | 62.2% |
Neutered female | 68 | 37.8% | |
History of contraception | Yes | 76 | 42.2% |
No | 18 | 10.0% | |
Unknown | 86 | 47.8% | |
Previous benign mammary lesions | Yes | 16 | 8.9% |
No | 164 | 91.1% | |
Parity | Nulliparous | 15 | 8.3% |
Multiparous | 21 | 11.7% | |
Unknown | 144 | 80.0% | |
Multicentricity | Multiple FMCs | 26 | 14.4% |
Single FMC | 154 | 85.6% | |
Pathologic tumor size | pT < 20 mm | 85 | 47.2% |
pT ≥ 20 mm | 95 | 52.8% | |
Pathologic nodal stage | pN+ (nodal metastasis) | 101 | 56.1% |
pN0 (no) | 20 | 11.1% | |
pNX (unknown) | 59 | 32.8% | |
Distant metastasis | M1 (yes) | 8 | 4.4% |
M0 (no) | 64 | 35.6% | |
MX (unknown) | 108 | 60.0% | |
WHO stage | Stage I | 45 | 25.0% |
Stage II | 23 | 12.8% | |
Stage III | 104 | 57.8% | |
Stage IV | 8 | 4.4% | |
WHO Histological type | Cribriform | 54 | 30.0% |
Comedocarcinoma | 50 | 27.8% | |
Solid | 27 | 15.0% | |
Mucinous | 15 | 8.3% | |
Tubulopapillary | 12 | 6.7% | |
Tubular | 9 | 5.0% | |
Papillary | 7 | 3.9% | |
Adenosquamous | 4 | 2.2% | |
Anaplastic | 2 | 1.1% | |
Elston and Ellis histological grade | Grade I | 10 | 5.5% |
Grade II | 82 | 45.6% | |
Grade III | 88 | 48.9% | |
Lymphovascular invasion | LVI+ | 110 | 61.1% |
LVI– | 70 | 38.9% | |
Tumor-associated inflammation | Absent to mild | 77 | 42.8% |
Moderate to severe | 103 | 57.2% | |
Estrogen Receptor (ERα) | ER+ (ER ≥ 10%) | 49 | 27.2% |
ER– (ER < 10%) | 131 | 72.8% | |
Progesterone Receptor (PR) | PR+ (PR ≥ 10%) | 13 | 7.2% |
PR– (PR < 10%) | 167 | 92.8% | |
HER2 Score | 0 | 103 | 57.2% |
1+ | 59 | 32.8% | |
2+ | 18 | 10.0% | |
3+ | 0 | 0 | |
Ki-67 | High Ki-67 (≥ 20%) | 169 | 93.9% |
Low Ki-67 (< 20%) | 11 | 6.1% | |
CK14 | CK14+ (≥ 15%) | 132 | 73.3% |
CK14– (< 15%) | 48 | 26.7% |